Association of choroid plexus volume with white matter microstructure, glymphatic function, and peripheral systemic inflammation in Alzheimer's disease.
{"title":"Association of choroid plexus volume with white matter microstructure, glymphatic function, and peripheral systemic inflammation in Alzheimer's disease.","authors":"Huwei Xia, Yijia Feng, Han Zhu, Danlu Yang, Chaoqun Wang, Zhipeng Wang, Hanyuan Zhang, Wenhao Pan, Yifan Zhao, Weihong Song, Yili Wu","doi":"10.1038/s41398-025-03432-1","DOIUrl":null,"url":null,"abstract":"<p><p>There has been growing attention to the role of choroid plexus (CP) in neurodegenerative diseases. However, its relationship with various pathophysiological changes in Alzheimer's Disease (AD) remains unclear. The purpose of this study is to investigate the relationship between CP volume (CPV) and white matter microstructure, cognitive function, glymphatic function, and peripheral systemic inflammation in AD. A total of 1351 participants with cognitive impairment who had available 3 T MRI scans were included from ADNI. CPV was automatically segmented using Gaussian Mixture Model (GMM). The Mini-Mental State Examination (MMSE) was employed to assess cognitive function. PSMD and DTI-ALPS based on DTI sequence were used to reflect white matter microstructure and glymphatic system. Peripheral systemic inflammation was represented by the neutrophil-lymphocyte ratio (NLR). Group comparisons and correlations were adjusted for age, sex, education and APOE4 carrier status. Participants with AD exhibited larger CPV (p < 0.001), higher PSMD (p < 0.001) and NLR (p = 0.035), and lower DTI-ALPS (p < 0.001) compared to those with subjective cognitive decline (SCD). CP enlargement was independently associated with higher PSMD (β = 0.223, p < 0.001) and worse cognitive function both cross-sectionally (β = -0.212, p < 0.001) and longitudinally (β = -0.214, p < 0.001). Furthermore, PSMD partially mediates the impact of CP enlargement on the severity and progression of cognitive function. Partial correlation analysis revealed that CP enlargement was associated with higher NLR (r = 0.101, p = 0.001) and lower DTI-ALPS (r = -0.241, p < 0.001). These findings suggest that CPV may reflect underlying pathophysiological processes in AD and serve as a biomarker for white matter damage and cognitive impairment progression.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"238"},"PeriodicalIF":5.8000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254307/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03432-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
There has been growing attention to the role of choroid plexus (CP) in neurodegenerative diseases. However, its relationship with various pathophysiological changes in Alzheimer's Disease (AD) remains unclear. The purpose of this study is to investigate the relationship between CP volume (CPV) and white matter microstructure, cognitive function, glymphatic function, and peripheral systemic inflammation in AD. A total of 1351 participants with cognitive impairment who had available 3 T MRI scans were included from ADNI. CPV was automatically segmented using Gaussian Mixture Model (GMM). The Mini-Mental State Examination (MMSE) was employed to assess cognitive function. PSMD and DTI-ALPS based on DTI sequence were used to reflect white matter microstructure and glymphatic system. Peripheral systemic inflammation was represented by the neutrophil-lymphocyte ratio (NLR). Group comparisons and correlations were adjusted for age, sex, education and APOE4 carrier status. Participants with AD exhibited larger CPV (p < 0.001), higher PSMD (p < 0.001) and NLR (p = 0.035), and lower DTI-ALPS (p < 0.001) compared to those with subjective cognitive decline (SCD). CP enlargement was independently associated with higher PSMD (β = 0.223, p < 0.001) and worse cognitive function both cross-sectionally (β = -0.212, p < 0.001) and longitudinally (β = -0.214, p < 0.001). Furthermore, PSMD partially mediates the impact of CP enlargement on the severity and progression of cognitive function. Partial correlation analysis revealed that CP enlargement was associated with higher NLR (r = 0.101, p = 0.001) and lower DTI-ALPS (r = -0.241, p < 0.001). These findings suggest that CPV may reflect underlying pathophysiological processes in AD and serve as a biomarker for white matter damage and cognitive impairment progression.
脉络膜丛(CP)在神经退行性疾病中的作用越来越受到关注。然而,其与阿尔茨海默病(AD)各种病理生理变化的关系尚不清楚。本研究旨在探讨AD患者脑CP体积(CPV)与脑白质微结构、认知功能、淋巴功能及周围系统炎症的关系。ADNI共纳入了1351名有3 T MRI扫描的认知障碍参与者。采用高斯混合模型(GMM)对CPV进行自动分割。采用简易精神状态检查(MMSE)评估认知功能。采用PSMD和基于DTI序列的DTI- alps来反映脑白质微观结构和淋巴系统。外周全身性炎症表现为中性粒细胞-淋巴细胞比值(NLR)。各组比较和相关性根据年龄、性别、教育程度和APOE4携带者状况进行调整。AD患者表现出更大的CPV (p
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.